NCT00936715View on ClinicalTrials.gov

Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States

PHASE2CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Chronic Hepatitis B

Interventions

DRUG

FTC/TDF

200/300 mg tablet administered orally once daily

Trial Locations (4)

10016

New York

33136

Miami

90048

Los Angeles

94115

San Francisco

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY

NCT00936715 - Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States | Biotech Hunter | Biotech Hunter